At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 197 enrolled
Drug / intervention
clonidine hydrochloride topical gel, 0.1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Single-arm Study to Evaluate the Long-term Use of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy
In Brief
A Phase 2 clinical trial evaluating clonidine hydrochloride topical gel, 0.1% for Painful Diabetic Neuropathy and Diabetes. Completed, enrolled 197 participants across 20 sites.
Detailed Summary
Study CLO-311 is a multicenter, open-label, single-arm study to assess the long-term use of Clonidine Gel in the treatment of pain associated with PDN. Subjects who have completed their 12-week participation in Study CLO-290 or Study CLO-310 are eligible to rollover into this study and receive active study drug in an open-label manner.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPainful Diabetic Neuropathy, Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedFeb 2015
Primary CompletionAug 2015
Study CompletionSep 2015
TodayJul 2026
First PostedFeb 4, 2015
Enrollment StartJun 1, 2014
Primary CompletionAug 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.4 years ago
Interventions
clonidine hydrochloride topical gel, 0.1%drug